COAG
Hemab Therapeutics completes $346.7M IPO, gains FDA breakthrough designation for sutacimig
Hemab Therapeutics, a clinical-stage biotech developing blood coagulation therapies, raised $346.7 million in its May 2026 IPO and began trading on Nasdaq under ticker COAG. The company also received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia, accelerating its pat…